Genmab A/S

Equities

GMAB

DK0010272202

Market Closed - Nasdaq Copenhagen Other stock markets 09:50:00 15/01/2026 pm IST			5-day change	1st Jan Change
2,164.00 ^DKK	-3.86%		+0.65%	+6.76%

12:38pm	Jyske Bank Raises Genmab Target Price to 2,300 Danish Kroner (2,000), Reiterates Hold - BN	FW
14/01	Genmab A/S Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 03:45 PM

Transcript : Genmab A/S Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 01

Published on 09/04/2024 at 10:35 pm IST

S&P Capital IQ

Presenter Speech
Vikram Purohit (Analysts)

Okay, everyone, let's go ahead and get started. Sorry for the slight delay here, but we'll make up for it on the back end. We have the team from Genmab up on

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Genmab A/S

12:38pm	Jyske Bank Raises Genmab Target Price to 2,300 Danish Kroner (2,000), Reiterates Hold - BN	FW
14/01	Genmab A/S Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 03:45 PM
08/01	UBS Raises Price Target for Genmab to 2,750 Danish Kroner (from 2,700), Reiterates Buy	FW
08/01	Genmab A/S Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence	CI
07/01	Genmab partners with Anthropic to accelerate research and development through agentic AI	RE
07/01	Genmab to Advance R&D Processes via AI Under New Anthropic Partnership	MT
07/01	Genmab, Anthropic to Use AI Tools in Clinical Development	MT
07/01	Genmab partners with Anthropic to accelerate R&D via agentic AI	RE
30/12	Genmab Faces 'Transformative' Year Ahead With Pivotal Trial Readouts, Truist Securities Says	MT
30/12	Genmab Kept at Buy as Truist Securities Forecasts 'Transformative' Year Ahead	MT
30/12	DNB Carnegie Trims Genmab PT, Maintains Hold Rating	MT
30/12	U.S. Futures, European Stocks Mixed	DJ
30/12	SHB: Genmab's Decision to Halt Acasunlimab Development Deemed Logical	FW
30/12	Denmark's Genmab Pulls Plug on Acasunlimab to Prioritize Late-stage Clinical Assets	MT
30/12	DNB Carnegie Lowers Price Target for Genmab to 1,985 Danish Kroner (from 2,050), Reiterates Hold	FW
30/12	Genmab to Cease Clinical Development of Acasunlimab Antibody	MT
29/12	Sector Update: Health Care Stocks Mixed Premarket Monday	MT
29/12	Genmab scraps development of experimental cancer therapy	RE
29/12	Genmab Discontinues Development of Tumor Treatment Acasunlimab	MT
29/12	Genmab Halts Development of Acasunlimab	FW
29/12	Genmab A/S Reaffirms Earnings Guidance for the Year 2025	CI
29/12	Genmab A/S to Discontinue Further Clinical Development of Acasunlimab Following A Portfolio Review	CI
19/12	Deutsche Bank Raises Target Price for Genmab to 2,400 Danish Kroner (2,000), Reiterates Buy	FW
12/12	Genmab Finalizes Tender Offer for Dutch Biotech Merus	MT
12/12	Genmab Completes Acquisition of Merus – Bolsters Portfolio with New Cancer Treatment	FW